A Multi-centre, Post Marketing Surveillance (PMS) Study That Will Collect Information on the Safety of GSK Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects Aged Between 9 and 25 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice
Condition: Cervical Intraepithelial Neoplasia Intervention: Other: Safety data collection (following routine vaccination) Sponsor: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cervical Cancer Vaccine | China Health | Genital Warts | Human Papillomavirus (HPV) | Marketing | Research | Study | Vaccines